ProCE Banner Activity

Phase III POSEIDON: First-line Durvalumab ± Tremelimumab + Chemotherapy in Metastatic NSCLC

Slideset Download
Conference Coverage
Durvalumab plus chemotherapy significantly improved PFS vs chemotherapy alone in patients with previously untreated metastatic NSCLC.

Share

Provided by

Provided by Clinical Care Options, LLC.
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Bayer Healthcare Pharma

Daiichi Sankyo, Inc.

Janssen administered by Scientific Affairs

Janssen Pharmaceutica NV

Millennium Pharmaceuticals Inc Subsidary of Takeda

Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme